Biomarkers for the Diagnosis of Transient Ischemic Attack

A transient ischemic attack (TIA) should be considered an emergency prevention opportunity in order to avoid recurrence as cerebral infarction (CI) serious (fatal or disabling). Indeed, about 20% of patients who have IC had in previous days or weeks, a TIA, which can be defined as a brief episode of cerebral dysfunction (or eye) do not result in permanent brain damage and thus no sequelae. Moreover, about 20% of ischemic events observed in practice are AIT. Despite the progress achieved in the treatment in the acute phase of an IC, prevention remains the most effective way to fight against this disease. This prevention can be put in place before the occurrence of a first IC, or after a first IC, especially when minor as a TIA.

However, the diagnosis of TIA remains particularly difficult and it is necessary now to identify new tools for the diagnosis of transient ischemic attack. Our study focused on the identification of one or more molecules (called biological markers or biomarkers) present in the bloodstream of patients, which will serve to facilitate the differential diagnosis of patients with TIA.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cerebrovascular Disorders Brain Diseases Brain Ischemia Cardiovascular Diseases Central Nervous System Diseases Ischemic Attack, Transient Nervous System Diseases Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Caen University Hospital

Caen, 14033, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

TIA lasting 18h
NIHSS < 0
MRI diffusion hypersignal less than 5 ml
follow up during 3 month
written informed consent prior to any study procedures

Exclusion criteria

Pregnant or breastfeeding women
major comorbidity (cancer, chronic infection)
recent trauma (less than 30 days) (cranial or extracranial)
Surgical or endovascular recent surgery(within 30 days).
Any old brain injury
Any acute pathology likely to induce inflammation, hemostasis disorders ...
Contraindications to MRI: Patients with a pacemaker, an implanted material activated by an electrical, magnetic or mechanical carriers hemostatic clips intracerebral aneurysms or carotid arteries, bearing orthopedic implants, claustrophobic ...
Patient under guardianship

Treatment and study plan

protein expression

Biological

Differential protein expression between the period of acute cerebral ischemia and the control period

Primary outcomes

change in proteomic analysis from MPs or from plasma.

Time frame: baseline and 72h after TAI and 90 days after TAI

Identify one or more markers of transient ischemic attack by a proteomic analysis from MPs or from plasma.

Sponsors and collaborators

Lead sponsor

University Hospital, Caen

Other

Registry information

Acronym: MAESTRO

Important dates

Study start: 2015
Primary completion: 2019
Study completion: 2019
First posted: Jun 15, 2016
Registry last updated: Sep 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed